Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders |
The results of matters submitted to a stockholder vote at the
Annual Meeting of Stockholders of the Company held on June1, 2017
(the 2017 Annual Meeting) in Boston, Massachusetts are as
follows:
Proposal 1: Election of Directors. Three nominees were
elected to serve on the Board until the 2020 annual meeting of
stockholders and until their successors are elected and qualified
with the votes set forth below:
| Nominee | For | Withheld | BrokerNon-Votes | |||||||||
|
Marc D. Beer |
27,002,323 | 698,246 | 1,265,363 | |||||||||
|
Dr.David Kupfer |
27,086,246 | 614,323 | 1,265,363 | |||||||||
|
Jan van Heek |
27,066,337 | 634,232 | 1,265,363 |
Proposal 2: Ratification of Deloitte Touche LLP as the
independent registered public accounting firm for the fiscal year
ended December31, 2017. The selection of Deloitte
Touche LLP as the Companys independent registered public
accounting firm for the fiscal year ended December31, 2017 was
ratified with the votes set forth below:
| For | Against | Abstain | ||||||
|
22,461,678 |
6,502,761 | 1,493 |
About Minerva Neurosciences, Inc. (NASDAQ:NERV)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein. Minerva Neurosciences, Inc. (NASDAQ:NERV) Recent Trading Information
Minerva Neurosciences, Inc. (NASDAQ:NERV) closed its last trading session down -0.05 at 9.95 with 2,876,446 shares trading hands.